C. Bellcross, April Hermstad, Christine Tallo, C. Leonard, Ioana Pencea, Christine Stanislaw
{"title":"A Randomized Trial to Maximize Identification and Genetic Counseling Referral of Women at Risk for Hereditary Breast and Ovarian Cancer","authors":"C. Bellcross, April Hermstad, Christine Tallo, C. Leonard, Ioana Pencea, Christine Stanislaw","doi":"10.31487/j.cor.2021.08.08","DOIUrl":null,"url":null,"abstract":"Purpose: The Breast Cancer Genetics Referral Screening Tool (B-RST™) has been endorsed as one of \nseveral validated screening tools to identify women appropriate for cancer genetics referral. We conducted \na randomized trial to determine the most effective means of follow-up for women who screened positive on \nB-RST™ 3.0.\nMethods: Women undergoing screening mammography at one of four Emory clinics were approached to \ncomplete the B-RST™. Participants who screened positive were randomized to one of three follow-up \ngroups: self-referral (Group 1), electronic health record (EHR) clinician messaging (Group 2), or direct \ncontact (Group 3). We compared genetic counseling appointment scheduling and completion rates by group.\nResults: Of 2,422 participants, 658 (27.2%) screened positive. Genetic counseling appointments were \nscheduled by 9.2%, 20.1% and 9.7% of Group 1, 2 and 3 participants respectively (p=0.001). Challenges to \nscheduling included lack of physician response to EHR messages and unsuccessful direct contact. Among \nthose scheduled (n=78) 70.5% completed the appointment, with no difference between the three groups.\nConclusion: B-RST™ can be used effectively in mammography settings to identify high-risk women for \ncancer genetics referral. Follow-up via EHR appears an acceptable and efficient approach, but additional \nstrategies are needed to facilitate completion of the genetic counseling process.","PeriodicalId":10487,"journal":{"name":"Clinical Oncology and Research","volume":"181 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Oncology and Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31487/j.cor.2021.08.08","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: The Breast Cancer Genetics Referral Screening Tool (B-RST™) has been endorsed as one of
several validated screening tools to identify women appropriate for cancer genetics referral. We conducted
a randomized trial to determine the most effective means of follow-up for women who screened positive on
B-RST™ 3.0.
Methods: Women undergoing screening mammography at one of four Emory clinics were approached to
complete the B-RST™. Participants who screened positive were randomized to one of three follow-up
groups: self-referral (Group 1), electronic health record (EHR) clinician messaging (Group 2), or direct
contact (Group 3). We compared genetic counseling appointment scheduling and completion rates by group.
Results: Of 2,422 participants, 658 (27.2%) screened positive. Genetic counseling appointments were
scheduled by 9.2%, 20.1% and 9.7% of Group 1, 2 and 3 participants respectively (p=0.001). Challenges to
scheduling included lack of physician response to EHR messages and unsuccessful direct contact. Among
those scheduled (n=78) 70.5% completed the appointment, with no difference between the three groups.
Conclusion: B-RST™ can be used effectively in mammography settings to identify high-risk women for
cancer genetics referral. Follow-up via EHR appears an acceptable and efficient approach, but additional
strategies are needed to facilitate completion of the genetic counseling process.